Essure Postmarket Study Enrollment Closes, Patient Follow-Ups Continue

Enrollment in Bayer’s postmarket surveillance study of its permanent implantable birth control device, Essure, has ended, and patient follow-ups are ongoing, FDA announced Friday (Jan. 10). More than 1,100 patients have been enrolled in the study, with 340 enrolled in the group of people who selected Essure and 788 in the group of participants who elected for laparoscopic tubal ligation. Essure came under intense scrutiny for causing serious pain and bleeding in many of the women who had been implanted...